Combination of Extracorporeal Life Support and Mesenchymal Stem Cell Therapy for Treatment of ARDS in Combat Casualties and Evacuation of Service Members with ARDS
Abstract
Transfer of injured service members from the Level 3 combat support hospital to level 4 and 5 medical facilities increase their chance of survival from devastating injuries. The aeromedical evacuation of patients with Acute Respiratory Distress Syndrome (ARDS) is sometimes beyond the possibilities because of limitations providing ventilator support in-flight with possible further deterioration of the patient status. Cell-based therapy with adult bone marrow-derived mesenchymal stromal cells (MSC) in experimental models of ARDS data suggest that administered allogeneic B-MSCs can mitigate hypoxemia and promote recovery. However, it is unknown how this new form of therapy can be used adjunct to current supportive measures for lung failure. Our objective is to complete a series of preclinical studies in large animal models using extracorporeal membrane oxygenation (ECMO) alone or in combination with MSC in sheep and pigs with ARDS. Our group had completed the first 19 experiments in which we demonstrated that 3.5 ug/kg of LPS infused i.v. to a sheep induces lung injury equivalent to a moderated ARDS. In the second group of studies, sheep in which a low flow-low pressure ECMO provided respiratory support (ALung) partially rescued the animals returned the parameters of respiratory function to typical values. It is our goal to now use ALung in a combination of MSCs to potentiate their protective effect.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2019
- Accession Number
- AD1108092
Entities
People
- Mauricio Rojas
Organizations
- University of Pittsburgh